Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for the Treatment of HER2-Negative, Low PD-L1 Expressing, Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Single-Arm Trial

NCT06932068 is registered in ClinicalTrials.gov with Qilu Hospital of Shandong University as lead sponsor.

NCT NCT06932068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06932068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for the Treatment of HER2-Negative, Low PD-L1 Expressing, Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Single-Arm Trial
Lead sponsor
Qilu Hospital of Shandong University
Phase
Phase 2
Overall status
Recruiting
Start date
March 26, 2025
Completion date
October 31, 2027
Enrollment
77 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

her2 negative, low pd-l1 expressing, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma